

G G Kenter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5881576/publications.pdf>

Version: 2024-02-01

80
papers

8,458
citations

53794

45
h-index

69250

77
g-index

80
all docs

80
docs citations

80
times ranked

8581
citing authors

#	ARTICLE	IF	CITATIONS
1	Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia. <i>New England Journal of Medicine</i> , 2009, 361, 1838-1847.	27.0	970
2	Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. <i>Gastroenterology</i> , 2004, 127, 17-25.	1.3	536
3	Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. <i>Lancet Oncology</i> , The, 2012, 13, 78-88.	10.7	431
4	High Number of Intraepithelial CD8+ Tumor-Infiltrating Lymphocytes Is Associated with the Absence of Lymph Node Metastases in Patients with Large Early-Stage Cervical Cancer. <i>Cancer Research</i> , 2007, 67, 354-361.	0.9	369
5	Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine. <i>Clinical Cancer Research</i> , 2008, 14, 178-187.	7.0	346
6	Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity. <i>Clinical Cancer Research</i> , 2008, 14, 169-177.	7.0	286
7	Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6. <i>Cancer Research</i> , 2004, 64, 5449-5455.	0.9	277
8	Tumor-Expressed B7-H1 and B7-DC in Relation to PD-1+ T-Cell Infiltration and Survival of Patients with Cervical Carcinoma. <i>Clinical Cancer Research</i> , 2009, 15, 6341-6347.	7.0	230
9	Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 11895-11899.	7.1	215
10	Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase II trial. <i>European Journal of Cancer</i> , 1999, 35, 946-952.	2.8	210
11	Human Leukocyte Antigen Class I, MHC Class I Chain-Related Molecule A, and CD8+/Regulatory T-Cell Ratio: Which Variable Determines Survival of Cervical Cancer Patients?. <i>Clinical Cancer Research</i> , 2008, 14, 2028-2035.	7.0	210
12	Association of cervical cancer with the presence of CD4 ⁺ regulatory T cells specific for human papillomavirus antigens. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 12087-12092.	7.1	201
13	A nerve-sparing radical hysterectomy: Guidelines and feasibility in Western patients. <i>International Journal of Gynecological Cancer</i> , 2001, 11, 180-186.	2.5	199
14	Oncogene alterations in carcinomas of the uterine cervix: overexpression of the epidermal growth factor receptor is associated with poor prognosis. <i>Clinical Cancer Research</i> , 1999, 5, 577-86.	7.0	186
15	Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. <i>Gynecologic Oncology</i> , 2012, 124, 496-501.	1.4	174
16	Prediction of a mismatch repair gene defect by microsatellite instability and immunohistochemical analysis in endometrial tumours from HNPCC patients. <i>Journal of Pathology</i> , 2000, 192, 328-335.	4.5	168
17	HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. <i>Journal of Translational Medicine</i> , 2013, 11, 88.	4.4	165
18	Association of antigen processing machinery and HLA class I defects with clinicopathological outcome in cervical carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 197-206.	4.2	160

#	ARTICLE	IF	CITATIONS
19	Overexpression of the $\alpha 2 \beta 6$ integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival. <i>Journal of Pathology</i> , 2007, 212, 316-324.	4.5	157
20	Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma. <i>Journal of Immunotherapy</i> , 2000, 23, 255-266.	2.4	151
21	An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1119-1129.	2.5	151
22	Survival analysis of endometrial carcinoma associated with hereditary nonpolyposis colorectal cancer. <i>International Journal of Cancer</i> , 2002, 102, 198-200.	5.1	119
23	Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. <i>Gynecologic Oncology</i> , 2012, 127, 462-466.	1.4	108
24	Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients. <i>Oncotimmunology</i> , 2017, 6, e1267095.	4.6	95
25	A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 1485-1492.	4.2	85
26	Genetic variation of antigen processing machinery components and association with cervical carcinoma. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 577-586.	2.8	82
27	Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment. <i>Clinical Cancer Research</i> , 2005, 11, 5273-5280.	7.0	80
28	Cytokine Profile of Cervical Cancer Cells. <i>Gynecologic Oncology</i> , 2001, 83, 235-243.	1.4	76
29	Nerve sparing radical hysterectomy: latest developments and historical perspective. <i>Critical Reviews in Oncology/Hematology</i> , 2003, 48, 271-279.	4.4	74
30	Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. <i>International Journal of Cancer</i> , 2008, 122, 486-494.	5.1	74
31	HLA and susceptibility to cervical neoplasia. <i>Human Immunology</i> , 1999, 60, 337-342.	2.4	72
32	The absence of CCL2 expression in cervical carcinoma is associated with increased survival and loss of heterozygosity at 17q11.2. <i>Journal of Pathology</i> , 2006, 208, 507-517.	4.5	72
33	An Unexpectedly Large Polyclonal Repertoire of HPV-Specific T Cells Is Poised for Action in Patients with Cervical Cancer. <i>Cancer Research</i> , 2010, 70, 2707-2717.	0.9	71
34	Objective assessment of sexual arousal in women with a history of hysterectomy. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2004, 111, 456-462.	2.3	70
35	HPV-based cervical screening: Rationale, expectations and future perspectives of the new Dutch screening programme. <i>Preventive Medicine</i> , 2019, 119, 108-117.	3.4	67
36	Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex genetic alterations in cervical cancer. <i>BMC Genomics</i> , 2007, 8, 53.	2.8	66

#	ARTICLE	IF	CITATIONS
37	Genetic alterations during the progression of squamous cell carcinomas of the uterine cervix. , 1999, 26, 346-354.		65
38	Recurrent integration of human papillomaviruses 16, 45, and 67 near translocation breakpoints in new cervical cancer cell lines. <i>Cancer Research</i> , 1999, 59, 5615-24.	0.9	64
39	Allelic loss and prognosis in carcinoma of the uterine cervix. , 1998, 79, 411-417.		63
40	Prognostic relevance of TGF- β 1 and PAI-1 in cervical cancer. <i>International Journal of Cancer</i> , 2004, 112, 1020-1028.	5.1	63
41	Survival of Patients with Ovarian Cancer due to a Mismatch Repair Defect. <i>Familial Cancer</i> , 2005, 4, 301-305.	1.9	63
42	Transforming growth factor- β 1 induces tumor stroma and reduces tumor infiltrate in cervical cancer. <i>Human Pathology</i> , 2002, 33, 1193-1199.	2.0	61
43	Detection of human papillomavirus type 18 E6 and E7-specific CD4+ T-helper 1 immunity in relation to health versus disease. <i>International Journal of Cancer</i> , 2006, 118, 950-956.	5.1	59
44	Nerve-Sparing Radical Hysterectomy: Local Recurrence Rate, Feasibility, and Safety in Cervical Cancer Patients Stage IA to IIA. <i>International Journal of Gynecological Cancer</i> , 2009, 19, 39-45.	2.5	55
45	Anatomical basis for nerve-sparing radical hysterectomy: immunohistochemical study of the pelvic autonomic nerves. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2005, 84, 868-874.	2.8	50
46	Substantial changes in gene expression of Wnt, MAPK and TNF α pathways induced by TGF- β 1 in cervical cancer cell lines. <i>Carcinogenesis</i> , 2005, 26, 1493-1502.	2.8	50
47	EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. <i>International Journal of Cancer</i> , 2006, 118, 2991-2998.	5.1	49
48	Elevated expression of SerpinA1 and SerpinA3 in HLA β -positive cervical carcinoma. <i>Journal of Pathology</i> , 2008, 215, 222-230.	4.5	46
49	The detection of circulating human papillomavirus-specific T cells is associated with improved survival of patients with deeply infiltrating tumors. <i>International Journal of Cancer</i> , 2011, 128, 379-389.	5.1	44
50	Efficacy of PD-1 blockade in cervical cancer is related to a CD8+FoxP3+CD25+ T-cell subset with operational effector functions despite high immune checkpoint levels. , 2019, 7, 43.		42
51	Surgically-treated early cervical cancer: Prognostic factors and the significance of depth of tumor invasion. <i>International Journal of Gynecological Cancer</i> , 1999, 9, 212-219.	2.5	41
52	Distinct regulation and impact of type 1 T-cell immunity against HPV16 L1, E2 and E6 antigens during HPV16-induced cervical infection and neoplasia. <i>International Journal of Cancer</i> , 2006, 118, 675-683.	5.1	41
53	Role of tumor-derived proinflammatory cytokines GM-CSF, TNF- α , and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. <i>Cancer</i> , 2007, 109, 556-565.	4.1	41
54	Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response. <i>Clinical Cancer Research</i> , 2008, 14, 7188-7195.	7.0	39

#	ARTICLE	IF	CITATIONS
55	Positioning of cervical carcinoma and Burkitt lymphoma translocation breakpoints with respect to the human papillomavirus integration cluster in FRA8C at 8q24.13. <i>Cancer Genetics and Cytogenetics</i> , 2004, 154, 1-9.	1.0	38
56	Expression of Smad2 and Smad4 in cervical cancer: absent nuclear Smad4 expression correlates with poor survival. <i>Modern Pathology</i> , 2008, 21, 866-875.	5.5	38
57	Expression of endoglin (CD105) in cervical cancer. <i>British Journal of Cancer</i> , 2009, 100, 1617-1626.	6.4	38
58	Neoadjuvant cisplatin and paclitaxel modulate tumor-infiltrating T cells in patients with cervical cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1759-1767.	4.2	38
59	Carcinoma of the uterine cervix stage I and IIA: results of surgical treatment: complications, recurrence and survival. <i>European Journal of Surgical Oncology</i> , 1989, 15, 55-60.	1.0	38
60	Skin reactions to human papillomavirus (HPV) 16 specific antigens intradermally injected in healthy subjects and patients with cervical neoplasia. <i>International Journal of Cancer</i> , 2008, 123, 146-152.	5.1	36
61	Safety of hormone replacement therapy following risk-reducing salpingo-oophorectomy: systematic review of literature and guidelines. <i>Climacteric</i> , 2019, 22, 352-360.	2.4	30
62	Serum HE4 is correlated to prognostic factors and survival in patients with endometrial cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 470, 655-664.	2.8	29
63	Simultaneous mapping of human papillomavirus integration sites and molecular karyotyping in short-term cultures of cervical carcinomas by using 49-color combined binary ratio labeling fluorescence in situ hybridization. <i>Cancer Genetics and Cytogenetics</i> , 2002, 134, 145-150.	1.0	25
64	Postoperative radiation therapy improves prognosis in patients with adverse risk factors in localized, early-stage cervical cancer: a retrospective comparative study. <i>International Journal of Gynecological Cancer</i> , 2006, 16, 1112-1118.	2.5	25
65	The long learning curve of gynaecological cancer surgery: an argument for centralisation. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2000, 107, 19-23.	2.3	23
66	â€˜DURVITâ€™: a phase-I trial of single low-dose durvalumab (Medi4736) IntraTumourally injected in cervical cancer: safety, toxicity and effect on the primary tumour- and lymph node microenvironment. <i>BMC Cancer</i> , 2018, 18, 888.	2.6	23
67	Rapid enrichment of human papillomavirus (HPV)-specific polyclonal T cell populations for adoptive immunotherapy of cervical cancer. <i>International Journal of Cancer</i> , 2005, 114, 274-282.	5.1	22
68	The Swift operation: a modification of the Leiden nerve-sparing radical hysterectomy. <i>Gynecological Surgery</i> , 2008, 5, 193-198.	0.9	18
69	High levels of soluble MICA are significantly related to increased disease-free and disease-specific survival in patients with cervical adenocarcinoma. <i>Tissue Antigens</i> , 2015, 85, 476-483.	1.0	17
70	Role of IL-12p40 in cervical carcinoma. <i>British Journal of Cancer</i> , 2012, 107, 1956-1962.	6.4	16
71	Evaluation of Immunological Cross-Reactivity between Clade A9 High-Risk Human Papillomavirus Types on the Basis of E6-Specific CD4 ⁺ Memory T Cell Responses. <i>Journal of Infectious Diseases</i> , 2010, 202, 1200-1211.	4.0	13
72	Surgical treatment of low stage cervical carcinoma: Back to the old days?. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 429-434.	2.5	9

#	ARTICLE	IF	CITATIONS
73	Results of radical surgery in women with stage IB2/IIA2 cervical cancer. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2016, 95, 166-172.	2.8	9
74	Lack of TNF α mRNA expression in cervical cancer is not associated with loss of heterozygosity at 6p21.3, inactivating mutations or promoter methylation. <i>Molecular Immunology</i> , 2008, 45, 152-159.	2.2	8
75	The case for completing the lymphadenectomy when positive lymph nodes are found during radical hysterectomy for cervical carcinoma. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2000, 79, 72-6.	2.8	7
76	Pathway Profiling and Rational Trial Design for Studies in Advanced Stage Cervical Carcinoma: A Review and a Perspective. <i>ISRN Oncology</i> , 2011, 2011, 1-13.	2.1	6
77	Experiences, adherence and satisfaction with a combined exercise and dietary intervention for patients with ovarian cancer undergoing chemotherapy: A mixed-methods study. <i>Gynecologic Oncology</i> , 2022, 165, 619-628.	1.4	4
78	Outcomes after Total versus Subtotal Abdominal Hysterectomy. <i>New England Journal of Medicine</i> , 2003, 348, 856-857.	27.0	3
79	Does anti-M μ llerian hormone predict change in menopausal symptoms following risk-reducing salpingo-oophorectomy? A prospective observational study. <i>Climacteric</i> , 2018, 21, 574-580.	2.4	3
80	Surgical treatment of low stage cervical carcinoma: Back to the old days?. <i>International Journal of Gynecological Cancer</i> , 2002, 12, 429-434.	2.5	3